Oncogenic Kras-induced leukemogeneis: hematopoietic stem cells as the initial target and lineage-specific progenitors as the potential targets for final leukemic transformation.
about
Oncogenic Kras expression in postmitotic neurons leads to S100A8-S100A9 protein overexpression and gliosisCombined MEK and JAK inhibition abrogates murine myeloproliferative neoplasm.Mutant Ikzf1, KrasG12D, and Notch1 cooperate in T lineage leukemogenesis and modulate responses to targeted agents.Prognostic impact of RAS mutations in patients with myelodysplastic syndrome.p53 loss promotes acute myeloid leukemia by enabling aberrant self-renewal.Constitutive MAP kinase activation in hematopoietic stem cells induces a myeloproliferative disorder.Induction of histiocytic sarcoma in mouse skeletal muscle.Endogenous oncogenic Nras mutation promotes aberrant GM-CSF signaling in granulocytic/monocytic precursors in a murine model of chronic myelomonocytic leukemiaSystemic activation of K-ras rapidly induces gastric hyperplasia and metaplasia in miceEndogenous oncogenic Nras mutation initiates hematopoietic malignancies in a dose- and cell type-dependent manner.Myelodysplasia in autosomal dominant and sporadic monocytopenia immunodeficiency syndrome: diagnostic features and clinical implications.Distinct requirements of hematopoietic stem cell activity and Nras G12D signaling in different cell types during leukemogenesis.Ras signaling contributes to survival of human T-cell leukemia/lymphoma virus type 1 (HTLV-1) Tax-positive T-cells.Deficiency of β Common Receptor Moderately Attenuates the Progression of Myeloproliferative Neoplasm in NrasG12D/+ Mice.Loss of Dnmt3a and endogenous Kras(G12D/+) cooperate to regulate hematopoietic stem and progenitor cell functions in leukemogenesisCis-regulatory mechanisms governing stem and progenitor cell transitionsCis-element mutated in GATA2-dependent immunodeficiency governs hematopoiesis and vascular integrityTargeting oncogenic Ras signaling in hematologic malignancies.Loss of CD44 attenuates aberrant GM-CSF signaling in Kras G12D hematopoietic progenitor/precursor cells and prolongs the survival of diseased animals.The IRP1-HIF-2α axis coordinates iron and oxygen sensing with erythropoiesis and iron absorptionInvolvement of KRAS G12A mutation in the IL-2-independent growth of a human T-LGL leukemia cell line, PLT-2.Defective K-Ras oncoproteins overcome impaired effector activation to initiate leukemia in vivoNotch1 gene mutations target KRAS G12D-expressing CD8+ cells and contribute to their leukemogenic transformation.Nras(G12D/+) promotes leukemogenesis by aberrantly regulating hematopoietic stem cell functionsEpigenetic Perturbations by Arg882-Mutated DNMT3A Potentiate Aberrant Stem Cell Gene-Expression Program and Acute Leukemia Development.Rasgrp1 mutation increases naive T-cell CD44 expression and drives mTOR-dependent accumulation of Helios⁺ T cells and autoantibodies.Hematopoietic expression of oncogenic BRAF promotes aberrant growth of monocyte-lineage cells resistant to PLX4720.Therapeutic targeting of microenvironmental interactions in leukemia: mechanisms and approaches.Loss of wild-type Kras promotes activation of all Ras isoforms in oncogenic Kras-induced leukemogenesis.Dnmt3a haploinsufficiency cooperates with oncogenic Kras to promote an early-onset T-cell acute lymphoblastic leukemia.Role of Ras/Raf/MEK/ERK signaling in physiological hematopoiesis and leukemia development.Ras/Raf/MEK/ERK Pathway Activation in Childhood Acute Lymphoblastic Leukemia and Its Therapeutic TargetingPhosphatase of regenerating liver in hematopoietic stem cells and hematological malignancies.Differential expression of CD133 based on microsatellite instability status in human colorectal cancer.Intra-tumor heterogeneity from a cancer stem cell perspective.Involvement of Gpr125 in the myeloid sarcoma formation induced by cooperating MLL/AF10(OM-LZ) and oncogenic KRAS in a mouse bone marrow transplantation model.Aberrant expression of RasGRP1 cooperates with gain-of-function NOTCH1 mutations in T-cell leukemogenesis.Modulation of anthracycline-induced cytotoxicity by targeting the prenylated proteome in myeloid leukemia cells.KRAS(G12V) enhances proliferation and initiates myelomonocytic differentiation in human stem/progenitor cells via intrinsic and extrinsic pathways.Cooperative loss of RAS feedback regulation drives myeloid leukemogenesis.
P2860
Q28589373-D6D1EC00-657B-4CA0-AFE3-C27D2998401FQ33685977-1EC50617-D852-4EC0-85ED-99D0204D84EFQ33739961-2E14DE1F-381F-4F1D-BCDB-9AD2036BD52FQ33871210-655D30EA-5FC0-41B9-B2E4-E0E4CD7BCAA7Q33953631-8B7EA7AD-8286-4F10-AA66-E1D0500AA5D7Q34099193-F798A176-F959-4F20-A3E4-08B6BAB6FE2FQ34406138-E7E97643-A01A-498E-99EC-8F6BE7068120Q34541588-358B2DCD-6A16-437D-9722-D005512EE1B0Q35099016-A5B6B0D2-D003-41FE-A431-CA99E3A951E8Q35112241-E6A233D8-5E64-43A8-9314-7E06D60A350EQ35143513-603711AC-ADD6-4FE9-B31B-AA3987A6CDC4Q35556969-AD8EA977-9CD4-496F-A084-29A880BDC4B8Q35757427-E31C5454-3CD6-4CCE-BFBF-2202C0DBB735Q35905350-81D0A8A3-6993-4299-A812-757B02E83485Q36021698-9594E27D-DF8F-4954-9B64-3FB73ADC6644Q36276945-43C05F1F-2C9E-4657-A4D7-131972554655Q36290255-9663A4E4-D666-451F-8180-EE3705C03644Q36352506-46C012EA-1EA7-44E2-AE45-27BA02773B55Q36700822-10EA18AE-CD51-40ED-9085-803A49B06DC9Q36728582-B069D662-A8EF-465D-AC1F-C4A07820BFC3Q36797103-C08411E5-F349-4D5F-BC18-800ADFC8AD03Q36928333-279DBF56-A73A-4D68-A71D-C6204ABF8EBDQ36947793-35ED7E51-53FE-4814-9B45-079484302914Q36962687-A19B4559-F610-4787-8B9C-47E4C32D6DD7Q37095702-53E52535-8789-4EE7-9F99-C357E293B351Q37381720-8EEC6E35-4D0C-4415-80DC-1CA7F41BA091Q37407268-A48EFEE4-58EC-4D51-A045-E61051EE6F09Q37562510-F8AC0260-7EB7-4095-B987-1BD16B2CF00CQ37651582-20C642D9-E256-46B5-9C26-E88082B4BBE5Q37733030-59436121-4614-4547-B0D9-250453FF5472Q37822317-7143049B-27C2-4CB5-A1C4-9F28027FBED2Q38227885-9DBC31B9-8CFE-4A68-87A3-DDD026F1A815Q38285175-842141D4-D736-45F3-87E6-FAF1D84C30C5Q38457404-4FB94A6F-5344-49A0-9A1F-BE06AE510FACQ39139446-DBB7D9CF-DEB6-409A-A653-C0D7168990B1Q39169829-AA53CE34-E42B-44AD-A98C-54707A335866Q39437389-04913822-3C5B-437E-8FC4-860F8BFF3B1BQ39474160-7178B8E4-6C42-48AE-8345-92673CAC4382Q39618355-E27F2C12-4968-4DEC-848A-B4710FBE1FDFQ40094852-86F4D602-E770-4683-98EF-7B655D001FD3
P2860
Oncogenic Kras-induced leukemogeneis: hematopoietic stem cells as the initial target and lineage-specific progenitors as the potential targets for final leukemic transformation.
description
article científic
@ca
article scientifique
@fr
articolo scientifico
@it
artigo científico
@pt
bilimsel makale
@tr
scientific article published on 09 December 2008
@en
vedecký článok
@sk
vetenskaplig artikel
@sv
videnskabelig artikel
@da
vědecký článek
@cs
name
Oncogenic Kras-induced leukemo ...... final leukemic transformation.
@en
Oncogenic Kras-induced leukemo ...... final leukemic transformation.
@nl
type
label
Oncogenic Kras-induced leukemo ...... final leukemic transformation.
@en
Oncogenic Kras-induced leukemo ...... final leukemic transformation.
@nl
prefLabel
Oncogenic Kras-induced leukemo ...... final leukemic transformation.
@en
Oncogenic Kras-induced leukemo ...... final leukemic transformation.
@nl
P2093
P2860
P1433
P1476
Oncogenic Kras-induced leukemo ...... final leukemic transformation.
@en
P2093
Harwin Sidik
Jing Zhang
Ken H Young
Mark D Fleming
Yangang Liu
P2860
P304
P356
10.1182/BLOOD-2008-01-134262
P407
P577
2008-12-09T00:00:00Z